Sweden In Vitro Diagnostics Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The European IVD market encompasses a wide range of diagnostic products including immunoassays, molecular diagnostics, clinical chemistry analyzers, and point-of-care testing devices. The broader European market generated approximately USD 32 billion in 2024, with projections suggesting growth to USD 34 billion in 2025 and reaching between USD 48.92 billion and USD 57 billion by 2034-2035 depending on the forecast source. The global IVD market, valued at USD 104.01 billion in 2025, reflects the expanding reliance on diagnostic testing across healthcare systems worldwide.

• •Europe accounted for roughly one-third of the global IVD market in recent years, with the European segment valued at approximately USD 32 billion in 2024
• •IVDs influence approximately 70% of clinical decision-making while accounting for less than 1% of total healthcare expenditure in the EU-27 and UK
• •The European market is expected to expand significantly through 2035, with estimates ranging from USD 48.92 billion to USD 57 billion by the mid-2030s

Demand for IVD testing is being propelled by an aging European population, increasing prevalence of chronic and infectious diseases, and growing emphasis on preventive and personalized medicine. Healthcare providers are increasingly adopting advanced diagnostic technologies to enable earlier disease detection and more targeted treatment decisions. The cost-effectiveness of IVDs relative to overall healthcare spending also makes them an attractive focus for healthcare system investments across Europe.

• •Aging demographics across Europe are driving higher demand for routine and specialized diagnostic testing
• •Advances in immunodiagnostics, molecular testing, and point-of-care devices are expanding the scope of conditions that can be diagnosed accurately and quickly
• •Focus on early disease detection and personalized medicine is increasing adoption of sophisticated IVD technologies

The IVD market is typically segmented by product type, including instruments, reagents, and consumables, as well as by testing technique such as immunodiagnostics, clinical chemistry, molecular diagnostics, and point-of-care testing. Western Europe, including Sweden and other Nordic countries, represents a mature segment with high adoption of advanced diagnostic technologies and strong regulatory frameworks. The European market as a whole is expected to grow at varying rates across subregions, with emerging markets in Eastern Europe showing faster adoption curves.

• •Major product categories include instruments and reagents/consumables, with immunodiagnostics (including ELISA and rapid tests) representing a significant share
• •Sweden and other Nordic countries maintain sophisticated healthcare infrastructure supporting advanced IVD adoption
• •The European market is projected to grow from approximately USD 32-34 billion in 2024-2025 toward USD 48.92-57 billion by 2034-2035

What are the recent trends and outlook?

The IVD industry is moving toward decentralized testing models, with point-of-care and at-home testing gaining prominence alongside traditional laboratory-based diagnostics. Digital connectivity and artificial intelligence are being integrated into diagnostic platforms to improve result interpretation and workflow efficiency. The global market is forecast to reach nearly USD 135.76 billion by 2035, reflecting sustained growth driven by technological innovation and expanding diagnostic indications.

• •Point-of-care testing and at-home diagnostics are growing segments, enabling faster results and reducing strain on centralized laboratories
• •Integration of AI and digital technologies is enhancing diagnostic accuracy, data management, and clinical decision support
• •The global IVD market is expected to expand from USD 104.01 billion in 2025 to nearly USD 135.76 billion by 2035 at a CAGR of 2.7%